Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein - McCue - 2014 - Haemophilia - Wiley Online Library Skip to Main Content Log in / Register Log In E-Mail Address Password Forgotten Password?

Remember Me RegisterInstitutional Login Home > Hematology > Hematology > Haemophilia > Early View > Abstract JOURNAL TOOLS Get New Content Alerts Get RSS feed Save to My Profile Get Sample Copy Recommend to Your Librarian JOURNAL MENUJournal HomeFIND ISSUESCurrent IssueAll Issues FIND ARTICLES Early ViewMost Accessed GET ACCESS Subscribe / Renew FOR CONTRIBUTORS OnlineOpenAuthor GuidelinesSubmit an Article ABOUT THIS JOURNAL Society InformationNewsOverviewEditorial BoardPermissionsAdvertiseContact SPECIAL FEATURES Christine Lee Haemophilia Journal AwardVisit BloodMed.comWiley Job NetworkNew Books in Hematology & TransfusionVirtual IssueJobs Original Article

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion proteinJ. McCue*, D. Osborne, J. Dumont, R. Peters, B. Mei, G. F. Pierce, K. Kobayashi andD. EuwartArticle first published online: 8 MAY 2014

DOI: 10.1111/hae.12451

© 2014 John Wiley & Sons Ltd

Issue

HaemophiliaEarly View (Online Version of Record published before inclusion in an issue)

Additional Information

How to CiteMcCue, J., Osborne, D., Dumont, J., Peters, R., Mei, B., Pierce, G. F., Kobayashi, K. and Euwart, D. (2014), Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein. Haemophilia. doi: 10.1111/hae.12451

Author Information

Biogen Idec, Cambridge, MA, USA

* Correspondence: Justin McCue, 14 Cambridge Center, Cambridge, MA 02142, USA.
Tel: (617) 679 3500; fax: (617) 679 2000;
e-mail: Justin.mccue@biogenidec.com

Publication HistoryArticle first published online: 8 MAY 2014Manuscript Accepted: 27 MAR 2014Funded byBiogen Idec SEARCH Search Scope All contentPublication titlesIn this journalIn this issue Search String Advanced >Saved Searches > SEARCH BY CITATION Volume: Issue: Page: ARTICLE TOOLSGet PDF (303K)Save to My ProfileE-mail Link to this ArticleExport Citation for this ArticleGet Citation AlertsRequest Permissions AbstractArticleReferencesCited By View Full Article (HTML) Enhanced Article (HTML) Get PDF (303K) Keywords:haemophilia B;human cell line;manufacturing;recombinant;rFIXFc;viral clearanceSummary

Recombinant factor IX Fc (rFIXFc) fusion protein is the first of a new class of bioengineered long-acting factors approved for the treatment and prevention of bleeding episodes in haemophilia B. The aim of this work was to describe the manufacturing process for rFIXFc, to assess product quality and to evaluate the capacity of the process to remove impurities and viruses. This manufacturing process utilized a transferable and scalable platform approach established for therapeutic antibody manufacturing and adapted for production of the rFIXFc molecule. rFIXFc was produced using a process free of human- and animal-derived raw materials and a host cell line derived from human embryonic kidney (HEK) 293H cells. The process employed multi-step purification and viral clearance processing, including use of a protein A affinity capture chromatography step, which binds to the Fc portion of the rFIXFc molecule with high affinity and specificity, and a 15 nm pore size virus removal nanofilter. Process validation studies were performed to evaluate identity, purity, activity and safety. The manufacturing process produced rFIXFc with consistent product quality and high purity. Impurity clearance validation studies demonstrated robust and reproducible removal of process-related impurities and adventitious viruses. The rFIXFc manufacturing process produces a highly pure product, free of non-human glycan structures. Validation studies demonstrate that this product is produced with consistent quality and purity. In addition, the scalability and transferability of this process are key attributes to ensure consistent and continuous supply of rFIXFc.

View Full Article (HTML) Enhanced Article (HTML) Get PDF (303K) More content like this Find more content: like this article Find more content written by:J. McCueD. OsborneJ. DumontR. PetersB. MeiG. F. PierceK. KobayashiD. EuwartAll Authors PublicationsBrowse by SubjectResources About UsHelpContact UsAgentsAdvertisersMediaPrivacyCookiesTerms & ConditionsSite Map Copyright © 1999-2014 John Wiley & Sons, Inc. All Rights Reserved. About WileyWiley.comWiley Job Network

View the original article here